Black Diamond Therapeutics
Founded 2016 · CIK 0001701541 · Biotech · Public
small molecule drugs targeting allosteric sites on cancer-associated proteins
blackdiamondtherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $140M
- 4 Form D · Dec 2019
- 82 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 4 granted · 36 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $7,101,210 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $42,499,973 | |
| Private capital raised | Form D · SEC | $84,999,941 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2796 | Enable Therapeutics LLC | — | — |
| 2797 | RGENE, INC. | — | — |
| 2798 | Immunocore Holdings plc | — | $140M |
| 2799 | Black Diamond Therapeutics | — | $140M |
| 2800 | VYNE Therapeutics Inc. | — | $139M |
| 2801 | Silverback Therapeutics | — | $139M |
| 2802 | VANQUA BIO, INC. | — | $136M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Ali BehbahaniDirector
- Brad BolzonDirector
- Bradley BolzonDirector
- Elizabeth BuckExecutive Officer
- David EpsteinDirector · Executive Officer
- Brent Hatzis-SchochExecutive Officer
- Samarth KulkarniDirector
- Thomas LeggettExecutive Officer
- Alexander MaywegDirector
- Garry MenzelDirector
- Fang NiExecutive Officer
- Christopher RobertsExecutive Officer
- Rajeev ShahDirector
Patents
- Quinoxaline Derivatives And Uses Thereofgranted
- Method Of Treating Cancers With Alkyne Substituted Quinazoline Derivativesgranted
- Alkynyl Quinazoline Compoundsapplication
- Alkynyl Quinazoline Compoundsgranted
- 6-AZA-QUINOLINE Derivatives And Related Usesapplication
- Polymorphs As Erbb Inhibitorsapplication
- Quinoxaline Derivatives And Uses Thereofapplication
- 6-SUBSTITUTED-9H-PURINE Derivatives And Related Usesapplication
- Tyrosine Kinase Inhibitor Compositions, Methods Of Making And Methods Of Useapplication
- Tyrosine Kinase Inhibitor Compositions, Methods Of Making And Methods Of Useapplication
- Tyrosine Kinase Inhibitor Compositions, Methods Of Making And Methods Of Usegranted
- Substituted Quinoline Derivatives And Related Usesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.